Astellas Pharma initiates trial of ASP2138 for HER2-negative gastric cancer
Astellas Pharma is conducting a double-blind study to evaluate ASP2138 in combination with chemotherapy and pembrolizumab for patients with HER2-negative and CLDN18.2-positive gastric or gastroesophageal junction cancer.